Coronary microvascular dysfunction beyond the spectrum of chronic coronary syndromes.

Marta Belmonte, Alberto Foà, Pasquale Paolisso, Luca Bergamaschi, Emanuele Gallinoro, Alberto Polimeni, Roberto Scarsini, Saverio Muscoli, Sara Amicone, Antonio De Vita, Angelo Villano, Francesco Angeli, Matteo Armillotta, Vincenzo Sucato, Saverio Tremamunno, Doralisa Morrone, Ciro Indolfi, Pasquale Perrone Filardi, Flavio Ribichini, Gaetano Antonio Lanza, Alaide Chieffo, Emanuele Barbato, Carmine Pizzi
{"title":"Coronary microvascular dysfunction beyond the spectrum of chronic coronary syndromes.","authors":"Marta Belmonte, Alberto Foà, Pasquale Paolisso, Luca Bergamaschi, Emanuele Gallinoro, Alberto Polimeni, Roberto Scarsini, Saverio Muscoli, Sara Amicone, Antonio De Vita, Angelo Villano, Francesco Angeli, Matteo Armillotta, Vincenzo Sucato, Saverio Tremamunno, Doralisa Morrone, Ciro Indolfi, Pasquale Perrone Filardi, Flavio Ribichini, Gaetano Antonio Lanza, Alaide Chieffo, Emanuele Barbato, Carmine Pizzi","doi":"10.1016/j.pcad.2024.10.006","DOIUrl":null,"url":null,"abstract":"<p><p>The prevalence of coronary microvascular dysfunction (CMD) beyond the spectrum of chronic coronary syndromes (CCS) is non-negligible, pertaining to pathophysiological and therapeutical implications. Thanks to the availability of accurate and safe non-invasive technique, CMD can be identified as a key player in heart failure, cardiomyopathies, Takotsubo syndrome, aortic stenosis. While CMD is widely recognized as a cause of myocardial ischemia leading to a worse prognosis even in the absence of obstructive coronary artery disease, the characterization of CMD patterns beyond CCS might provide valuable insights on the underlying disease progression, being potentially a \"red flag\" of adverse cardiac remodeling and a major determinant of response to therapy and outcomes. In this review, we aimed to provide an overview of the latest evidence on the prevalence, mechanistic and prognostic implications of CMD beyond the spectrum of CCS (i.e. heart failure, cardiomyopathies, Takotsubo syndrome, aortic stenosis).</p>","PeriodicalId":94178,"journal":{"name":"Progress in cardiovascular diseases","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Progress in cardiovascular diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.pcad.2024.10.006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The prevalence of coronary microvascular dysfunction (CMD) beyond the spectrum of chronic coronary syndromes (CCS) is non-negligible, pertaining to pathophysiological and therapeutical implications. Thanks to the availability of accurate and safe non-invasive technique, CMD can be identified as a key player in heart failure, cardiomyopathies, Takotsubo syndrome, aortic stenosis. While CMD is widely recognized as a cause of myocardial ischemia leading to a worse prognosis even in the absence of obstructive coronary artery disease, the characterization of CMD patterns beyond CCS might provide valuable insights on the underlying disease progression, being potentially a "red flag" of adverse cardiac remodeling and a major determinant of response to therapy and outcomes. In this review, we aimed to provide an overview of the latest evidence on the prevalence, mechanistic and prognostic implications of CMD beyond the spectrum of CCS (i.e. heart failure, cardiomyopathies, Takotsubo syndrome, aortic stenosis).

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
超越慢性冠状动脉综合征范围的冠状动脉微血管功能障碍。
冠状动脉微血管功能障碍(CMD)的发病率超出了慢性冠状动脉综合征(CCS)的范围,其对病理生理学和治疗学的影响不容忽视。由于有了准确、安全的无创技术,CMD 可以被确定为心力衰竭、心肌病、Takotsubo 综合征和主动脉瓣狭窄的关键因素。虽然 CMD 被广泛认为是导致心肌缺血的原因之一,即使没有阻塞性冠状动脉疾病,也会导致预后恶化,但对 CCS 之外的 CMD 模式进行定性,可能会为潜在的疾病进展提供有价值的见解,有可能成为不良心脏重塑的 "红旗",并成为治疗反应和预后的主要决定因素。在这篇综述中,我们旨在概述 CCS 范围以外的 CMD(即心力衰竭、心肌病、Takotsubo 综合征、主动脉瓣狭窄)的患病率、机理和预后影响方面的最新证据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Cardiovascular outcomes among giant cell myocarditis compared with cardiac sarcoidosis: A propensity score-matched analysis. Assorted topics III 2024. Of meat & molecules. Safety outcomes of oral anticoagulants in patients with an indication of anti-coagulants after TAVR: A meta-analysis. Cardiovascular-kidney-metabolic syndrome - An integrative review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1